Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Cross Above 200-Day Moving Average – Should You Sell?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $49.66 and traded as high as $51.06. Supernus Pharmaceuticals shares last traded at $50.96, with a volume of 873,941 shares.

Analysts Set New Price Targets

SUPN has been the subject of a number of research reports. Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Stifel Nicolaus boosted their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research report on Friday, December 19th. Finally, Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Stock Performance

The firm’s 50-day moving average price is $51.19 and its two-hundred day moving average price is $49.66. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of -74.94, a PEG ratio of 1.57 and a beta of 0.73.

Insider Activity

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 35,000 shares of the stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the completion of the transaction, the chief executive officer owned 958,100 shares of the company’s stock, valued at $48,259,497. This trade represents a 3.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Georges Gemayel sold 10,000 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $53.71, for a total transaction of $537,100.00. Following the transaction, the director directly owned 28,159 shares of the company’s stock, valued at approximately $1,512,419.89. This trade represents a 26.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 120,881 shares of company stock worth $6,139,356. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Hantz Financial Services Inc. boosted its stake in Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 281 shares during the period. Rockefeller Capital Management L.P. boosted its stake in Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 660 shares during the period. Torren Management LLC purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth about $49,000. USA Financial Formulas purchased a new position in Supernus Pharmaceuticals during the third quarter worth about $50,000. Finally, EverSource Wealth Advisors LLC purchased a new position in Supernus Pharmaceuticals during the second quarter worth about $51,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.